Finance the Shockwave System Banks Do Not Understand

Get Your Free Quote

No cost, no obligation, no credit impact.

Bank-level encryption. Your info is confidential.

The first decision in a lithotripsy purchase is not the brand, it is the delivery model. A fixed room install puts a system like the Dornier Delta III or Storz Modulith SLX-F2 in a dedicated stone suite, integrated with its own fluoroscopy and ultrasound localization and a treatment table. You control the schedule, you keep every dollar of the facility component, and the machine is available whenever a case comes in. The tradeoff is that you carry the full capital cost against your own case volume.

The mobile model spreads a lithotripter across several practices or hospitals on a route, the system arrives in a coach on scheduled days. It lowers the per-site capital burden and makes sense for a group whose stone volume alone would not justify a dedicated machine. The tradeoff is that you share the schedule and, in a per-case arrangement, you may be paying a third party's margin on every treatment.

Both models are financeable, and we structure them differently. A fixed install is underwritten against one practice's volume and usually runs a longer term. A mobile configuration can be financed as the machine plus the coach, with the term sized to the combined case flow across sites. The right answer depends on how many stone cases you actually treat, your referral base, and whether you want to own the asset or keep flexibility. We help you match the financing to the model, then place it with a lender who funds that structure.

Representative lithotripsy deals placed through our lender network.

1. Dornier Delta III with integrated table and imaging, Phoenix urology group. A five-urologist practice, fifteen years in operation, financed $465,000 for a fixed stone room, with the term matched to case volume rather than a rigid bank schedule. Lead credit in the low 740s. Approved at 5.74% APR over 84 months with 10% down.

2. Refurbished Storz Modulith SLX-F2, two-partner urology. Nine years in practice, credit in the low 710s, financed $210,000 for a dedicated ESWL suite. Approved at 6.14% APR over 72 months with 10% down.

3. Dornier Delta II upgraded to Delta III, established group. Twenty-two years in operation, personal credit in the high 760s, financed $325,000 for the platform upgrade. Approved at 5.49% APR over 60 months with 5% down.

4. Medispec Econolith 3000, newer practice exploring mobile. Four years in operation, personal credit in the high 680s, financed $178,000 for a compact system to serve two sites. Approved at 6.64% APR over 66 months with 15% down.

These reflect real placement structures, not guaranteed rates. Your terms depend on the practice, the system, the delivery model, and current lender appetite.

The economics of owning a lithotripter come down to case volume and captured margin. Each ESWL treatment carries a facility and technical component, and when you own the machine, that component stays in the practice instead of going to a hospital or a mobile provider on a per-case fee. A group treating a steady flow of stone patients, especially one that currently sends those cases out or rents a mobile system, is often paying more per year in referral loss and per-case fees than a financed machine would cost.

Run the comparison directly. A $325,000 Dornier Delta III financed at 5.49% over 60 months costs roughly $6,200 a month. A practice with real stone volume clears that from the ESWL cases it already treats, and everything above the payment is margin it used to give away. The lumpiness of stone volume is exactly why we structure the term to case flow, so a slower quarter does not strain the payment.

On tax, a lithotripter placed in service generally qualifies for Section 179 expensing, and 100% bonus depreciation currently applies to qualifying equipment. With the Section 179 cap now above $2.5 million, financing a $325,000 system can shelter a large share of first-year income while you paid only a down payment in cash. You deploy a fraction of the capital, the machine earns immediately, and the deduction lands in year one. Confirm the current figures with your CPA.

Lithotripsy is where generalist bank financing breaks down most often, so this is exactly the deal to bring to a broker. The machine is expensive and specialized, the collateral is hard for a community lender to value, and stone case volume is unfamiliar to a generalist underwriter. Left to a bank, a $400,000 Delta III often gets a decline or a punishing short term.

We route these to the lenders in our network of more than 500 who fund urology and imaging capex and know what an ESWL system is worth. For an established group, that means a competitive rate from 5.49% APR and a longer term, 72 to 84 months, sized against real case volume. We can build a lighter early period so payments start modest while a new stone program ramps. We finance fixed room installs and mobile coach configurations, roll in imaging integration and installation, and blend refurbished and new components where it makes sense. Most approvals start with a soft pull, so shopping the deal does not touch your credit. You decide on the system and the delivery model. We find the lender who understands stone capex and structure the payment so the machine earns more than it costs from the start.